BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

794 related articles for article (PubMed ID: 31042405)

  • 1. Multicenter Preclinical Validation of BET Inhibition for the Treatment of Pulmonary Arterial Hypertension.
    Van der Feen DE; Kurakula K; Tremblay E; Boucherat O; Bossers GPL; Szulcek R; Bourgeois A; Lampron MC; Habbout K; Martineau S; Paulin R; Kulikowski E; Jahagirdar R; Schalij I; Bogaard HJ; Bartelds B; Provencher S; Berger RMF; Bonnet S; Goumans MJ
    Am J Respir Crit Care Med; 2019 Oct; 200(7):910-920. PubMed ID: 31042405
    [No Abstract]   [Full Text] [Related]  

  • 2. CDC2 Is an Important Driver of Vascular Smooth Muscle Cell Proliferation via FOXM1 and PLK1 in Pulmonary Arterial Hypertension.
    Pal-Ghosh R; Xue D; Warburton R; Hill N; Polgar P; Wilson JL
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34203295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxidized DNA Precursors Cleanup by NUDT1 Contributes to Vascular Remodeling in Pulmonary Arterial Hypertension.
    Vitry G; Paulin R; Grobs Y; Lampron MC; Shimauchi T; Lemay SE; Tremblay E; Habbout K; Awada C; Bourgeois A; Nadeau V; Paradis R; Breuils-Bonnet S; Roux-Dalvai F; Orcholski M; Potus F; Provencher S; Boucherat O; Bonnet S
    Am J Respir Crit Care Med; 2021 Mar; 203(5):614-627. PubMed ID: 33021405
    [No Abstract]   [Full Text] [Related]  

  • 4. HMGB1 down-regulation mediates terameprocol vascular anti-proliferative effect in experimental pulmonary hypertension.
    Nogueira-Ferreira R; Ferreira-Pinto MJ; Silva AF; Vitorino R; Justino J; Costa R; Moreira-Gonçalves D; Quignard JF; Ducret T; Savineau JP; Leite-Moreira AF; Ferreira R; Henriques-Coelho T
    J Cell Physiol; 2017 Nov; 232(11):3128-3138. PubMed ID: 28036116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Noncanonical HIPPO/MST Signaling via BUB3 and FOXO Drives Pulmonary Vascular Cell Growth and Survival.
    Kudryashova TV; Dabral S; Nayakanti S; Ray A; Goncharov DA; Avolio T; Shen Y; Rode A; Pena A; Jiang L; Lin D; Baust J; Bachman TN; Graumann J; Ruppert C; Guenther A; Schmoranzer M; Grobs Y; Eve Lemay S; Tremblay E; Breuils-Bonnet S; Boucherat O; Mora AL; DeLisser H; Zhao J; Zhao Y; Bonnet S; Seeger W; Pullamsetti SS; Goncharova EA
    Circ Res; 2022 Mar; 130(5):760-778. PubMed ID: 35124974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Participation of PLK1 and FOXM1 in the hyperplastic proliferation of pulmonary artery smooth muscle cells in pulmonary arterial hypertension.
    Wilson JL; Wang L; Zhang Z; Hill NS; Polgar P
    PLoS One; 2019; 14(8):e0221728. PubMed ID: 31437238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Smooth muscle cell-specific FoxM1 controls hypoxia-induced pulmonary hypertension.
    Dai J; Zhou Q; Tang H; Chen T; Li J; Raychaudhuri P; Yuan JX; Zhou G
    Cell Signal; 2018 Nov; 51():119-129. PubMed ID: 30092353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implication of Inflammation and Epigenetic Readers in Coronary Artery Remodeling in Patients With Pulmonary Arterial Hypertension.
    Meloche J; Lampron MC; Nadeau V; Maltais M; Potus F; Lambert C; Tremblay E; Vitry G; Breuils-Bonnet S; Boucherat O; Charbonneau E; Provencher S; Paulin R; Bonnet S
    Arterioscler Thromb Vasc Biol; 2017 Aug; 37(8):1513-1523. PubMed ID: 28473439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical Investigation of Trifluoperazine as a Novel Therapeutic Agent for the Treatment of Pulmonary Arterial Hypertension.
    Grobs Y; Awada C; Lemay SE; Romanet C; Bourgeois A; Toro V; Nadeau V; Shimauchi K; Orcholski M; Breuils-Bonnet S; Tremblay E; Provencher S; Paulin R; Boucherat O; Bonnet S
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FOXM1 promotes pulmonary artery smooth muscle cell expansion in pulmonary arterial hypertension.
    Bourgeois A; Lambert C; Habbout K; Ranchoux B; Paquet-Marceau S; Trinh I; Breuils-Bonnet S; Paradis R; Nadeau V; Paulin R; Provencher S; Bonnet S; Boucherat O
    J Mol Med (Berl); 2018 Feb; 96(2):223-235. PubMed ID: 29290032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stox1 induced the proliferation and cell cycle arrest in pulmonary artery smooth muscle cells via AKT signaling pathway.
    Xu Y; Sun Z; Wang Q; Wang T; Liu Y; Yu F
    Vascul Pharmacol; 2019 Sep; 120():106568. PubMed ID: 31207359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of DP1 Aggravates Vascular Remodeling in Pulmonary Arterial Hypertension via mTORC1 Signaling.
    He Y; Zuo C; Jia D; Bai P; Kong D; Chen D; Liu G; Li J; Wang Y; Chen G; Yan S; Xiao B; Zhang J; Piao L; Li Y; Deng Y; Li B; Roux PP; Andreasson KI; Breyer RM; Su Y; Wang J; Lyu A; Shen Y; Yu Y
    Am J Respir Crit Care Med; 2020 May; 201(10):1263-1276. PubMed ID: 31917615
    [No Abstract]   [Full Text] [Related]  

  • 13. Blockade of JAK2 protects mice against hypoxia-induced pulmonary arterial hypertension by repressing pulmonary arterial smooth muscle cell proliferation.
    Zhang L; Wang Y; Wu G; Rao L; Wei Y; Yue H; Yuan T; Yang P; Xiong F; Zhang S; Zhou Q; Chen Z; Li J; Mo BW; Zhang H; Xiong W; Wang CY
    Cell Prolif; 2020 Feb; 53(2):e12742. PubMed ID: 31943454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MnTBAP Reverses Pulmonary Vascular Remodeling and Improves Cardiac Function in Experimentally Induced Pulmonary Arterial Hypertension.
    Gomez-Puerto MC; Sun XQ; Schalij I; Orriols M; Pan X; Szulcek R; Goumans MJ; Bogaard HJ; Zhou Q; Ten Dijke P
    Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32531895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LRP1 Deficiency in Vascular SMC Leads to Pulmonary Arterial Hypertension That Is Reversed by PPARγ Activation.
    Calvier L; Boucher P; Herz J; Hansmann G
    Circ Res; 2019 Jun; 124(12):1778-1785. PubMed ID: 31023188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Astragaloside IV attenuates hypoxia‑induced pulmonary vascular remodeling via the Notch signaling pathway.
    Yao J; Fang X; Zhang C; Yang Y; Wang D; Chen Q; Zhong G
    Mol Med Rep; 2021 Jan; 23(1):. PubMed ID: 33236156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dacomitinib, a new pan-EGFR inhibitor, is effective in attenuating pulmonary vascular remodeling and pulmonary hypertension.
    Yu X; Zhao X; Zhang J; Li Y; Sheng P; Ma C; Zhang L; Hao X; Zheng X; Xing Y; Qiao H; Qu L; Zhu D
    Eur J Pharmacol; 2019 May; 850():97-108. PubMed ID: 30753867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasminogen activator Inhibitor-2 inhibits pulmonary arterial smooth muscle cell proliferation in pulmonary arterial hypertension via PI3K/Akt and ERK signaling.
    Zhang S; Wang J; Qi X; Tao X; Xie W; Wan J; Shen YH; Zhai Z
    Exp Cell Res; 2021 Jan; 398(1):112392. PubMed ID: 33227315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dihydroartemisinin Attenuates Pulmonary Hypertension Through Inhibition of Pulmonary Vascular Remodeling in Rats.
    Tang M; Wang R; Feng P; Dong Q; Chen W; Zhao Y; Li A; Li H; Chen J; Huang W
    J Cardiovasc Pharmacol; 2020 Sep; 76(3):337-348. PubMed ID: 32569012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-143 Activation Regulates Smooth Muscle and Endothelial Cell Crosstalk in Pulmonary Arterial Hypertension.
    Deng L; Blanco FJ; Stevens H; Lu R; Caudrillier A; McBride M; McClure JD; Grant J; Thomas M; Frid M; Stenmark K; White K; Seto AG; Morrell NW; Bradshaw AC; MacLean MR; Baker AH
    Circ Res; 2015 Oct; 117(10):870-883. PubMed ID: 26311719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.